

Laboratory Medicine in the Era of Disruptive Technology

# LMCE 2017 & KSLM 58<sup>th</sup> Annual Meeting

October 18-20, 2017  
Grand Walkerhill Seoul, Korea  
[www.lmce-kslm.org](http://www.lmce-kslm.org)

## illumina

### Product Highlights

### TruSight Tumor® 170




Comprehensive genomic results from limited tumour tissue. Introducing TruSight Tumor® 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.

### TruSight® One Expanded



#### TruSight® One Workflow

The Illumina TruSight® One Workflow provides a solution for every step from library preparation to data analysis and data reporting.



Uncover rare and undiagnosed disease with next-generation sequencing, introducing TruSight® One Expanded, targeted sequencing for >86,000 exons for >6,700 genes. The TruSight® One Expanded panel offers the highest number of clinically relevant genes in a targeted panel on the market today, an increase of 40% in content compared to TruSight® One.